Skip to main content
Passa alla visualizzazione normale.

SALVATRICE MANCUSO

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

  • Authors: Arcaini, L; Vallisa, D;Rattotti,S;Ferretti,VV; Ferreri,AJM;Bernuzzi,P;Merli,M;Varettoni,M; Chiappella,A;Ambrosetti,A;Tucci,A;Rusconi,A;Visco,S;Spina,L; Cabras,G;Luminari,S; Tucci,M; Musto,P;Ladetto,M;Merli,F;Stelitano,C;d’Arco,A;Rigacci,L;Levis,A; Rossi,D;Spedini,P;Mancuso,S;Marino,D Bruno,R;Baldini, L; Pulsoni,A
  • Publication year: 2014
  • Type: Articolo in rivista (Articolo in rivista)
  • Key words: Antiviral Treatment, indolent B cell lymphoma,HCv infection
  • OA Link: http://hdl.handle.net/10447/102123

Abstract

Background: Tumor regression after antiviral therapy (AT) is in favor of an etiological role of hepatitis C virus (HCV) in non-Hodgkin's B-cell lymphomas (NHL). Patients and methods: We carried out a cohort study of 704 consecutive HIV-negative, HCV-positive patients with indolent NHL diagnosed and treated from 1993 to 2009 in 39 centers of the Fondazione Italiana Linfomi; 134 patients were managed with AT for lymphoma control. Results: For entire cohort, 5-year overall survival (OS) was 78% [95% confidence interval (CI): 74%-82%] and 5-year progression-free survival (PFS) was 48% (95% CI: 44%-53%). In multivariate analysis, the use of AT during the patients' life had positive impact on OS. Forty-four of the 100 patients treated with first-line AT achieved a complete remission (CR) and 33 a partial response (PR). HCV-RNA clearance was achieved in 80 patients and was related to lymphoma response. At a median follow-up of 3.6 years, 5-year PFS was 63% (95% CI: 50%-73%). CR + PR rate was ...